Thus, we found that CX3CL1-knockdown abrogated MSC inhibition of colorectal cancer, improvement of sensitivity to αPD1 treatment, and modification of CX3CR1high macrophages. The gene discussed is CX3CL1; the disease is colorectal cancer.